Molecular pathology tests - Revision history

Jensflorian: /* Neuropathology */ wikify

2017-03-23T11:25:14Z

Neuropathology: wikify

← Older revision		Revision as of 11:25, 23 March 2017
Line 180:		Line 180:
	\| Diagnostic (K27M-mutant glioma of the midline / pediatric glioblastoma). <ref>{{Cite journal \| last1 = Sturm \| first1 = D. \| last2 = Witt \| first2 = H. \| last3 = Hovestadt \| first3 = V. \| last4 = Khuong-Quang \| first4 = DA. \| last5 = Jones \| first5 = DT. \| last6 = Konermann \| first6 = C. \| last7 = Pfaff \| first7 = E. \| last8 = Tönjes \| first8 = M. \| last9 = Sill \| first9 = M. \| title = Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. \| journal = Cancer Cell \| volume = 22 \| issue = 4 \| pages = 425-37 \| month = Oct \| year = 2012 \| doi = 10.1016/j.ccr.2012.08.024 \| PMID = 23079654 }}</ref>		\| Diagnostic (K27M-mutant glioma of the midline / pediatric glioblastoma). <ref>{{Cite journal \| last1 = Sturm \| first1 = D. \| last2 = Witt \| first2 = H. \| last3 = Hovestadt \| first3 = V. \| last4 = Khuong-Quang \| first4 = DA. \| last5 = Jones \| first5 = DT. \| last6 = Konermann \| first6 = C. \| last7 = Pfaff \| first7 = E. \| last8 = Tönjes \| first8 = M. \| last9 = Sill \| first9 = M. \| title = Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. \| journal = Cancer Cell \| volume = 22 \| issue = 4 \| pages = 425-37 \| month = Oct \| year = 2012 \| doi = 10.1016/j.ccr.2012.08.024 \| PMID = 23079654 }}</ref>
	\|-		\|-
	\| MGMT		\| [[MGMT]]
	\| Methylation-specific PCR, Pyroseq.		\| Methylation-specific PCR, Pyroseq.
	\| [[glioblastoma]], [[astrocytoma]] & [[oligodendroglioma]].		\| [[glioblastoma]], [[astrocytoma]] & [[oligodendroglioma]].

Jensflorian: /* Neuropathology */ wikify

2017-03-22T13:28:56Z

Neuropathology: wikify

← Older revision		Revision as of 13:28, 22 March 2017
Line 170:		Line 170:
	\| Prognostic and predicts response to PCV treatment.<ref>{{Cite journal \| last1 = Cairncross \| first1 = G. \| last2 = Wang \| first2 = M. \| last3 = Shaw \| first3 = E. \| last4 = Jenkins \| first4 = R. \| last5 = Brachman \| first5 = D. \| last6 = Buckner \| first6 = J. \| last7 = Fink \| first7 = K. \| last8 = Souhami \| first8 = L. \| last9 = Laperriere \| first9 = N. \| title = Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. \| journal = J Clin Oncol \| volume = 31 \| issue = 3 \| pages = 337-43 \| month = Jan \| year = 2013 \| doi = 10.1200/JCO.2012.43.2674 \| PMID = 23071247 }}</ref>		\| Prognostic and predicts response to PCV treatment.<ref>{{Cite journal \| last1 = Cairncross \| first1 = G. \| last2 = Wang \| first2 = M. \| last3 = Shaw \| first3 = E. \| last4 = Jenkins \| first4 = R. \| last5 = Brachman \| first5 = D. \| last6 = Buckner \| first6 = J. \| last7 = Fink \| first7 = K. \| last8 = Souhami \| first8 = L. \| last9 = Laperriere \| first9 = N. \| title = Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. \| journal = J Clin Oncol \| volume = 31 \| issue = 3 \| pages = 337-43 \| month = Jan \| year = 2013 \| doi = 10.1200/JCO.2012.43.2674 \| PMID = 23071247 }}</ref>
	\|-		\|-
	\| IDH1/2		\| [[IDH_mutation\|IDH1/2]]
	\| PCR + [[IDH-1\|IDH1 R132H antibody]].		\| PCR + [[IDH-1\|IDH1 R132H antibody]].
	\| [[oligodendroglioma]] & [[astrocytoma]].		\| [[oligodendroglioma]] & [[astrocytoma]].

Jensflorian: /* Neuropathology */ update

2017-03-22T11:40:00Z

Neuropathology: update

← Older revision		Revision as of 11:40, 22 March 2017
Line 181:		Line 181:
	\|-		\|-
	\| MGMT		\| MGMT
	\| Methylation-specific.		\| Methylation-specific PCR, Pyroseq.
	\| [[glioblastoma]], [[astrocytoma]] & [[oligodendroglioma]].		\| [[glioblastoma]], [[astrocytoma]] & [[oligodendroglioma]].
	\| Prognostic & predicts treatment to Temozolomide treatment.<ref>{{Cite journal \| last1 = Stupp \| first1 = R. \| last2 = Hegi \| first2 = ME. \| last3 = Mason \| first3 = WP. \| last4 = van den Bent \| first4 = MJ. \| last5 = Taphoorn \| first5 = MJ. \| last6 = Janzer \| first6 = RC. \| last7 = Ludwin \| first7 = SK. \| last8 = Allgeier \| first8 = A. \| last9 = Fisher \| first9 = B. \| title = Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. \| journal = Lancet Oncol \| volume = 10 \| issue = 5 \| pages = 459-66 \| month = May \| year = 2009 \| doi = 10.1016/S1470-2045(09)70025-7 \| PMID = 19269895 }}</ref>		\| Prognostic & predicts treatment to Temozolomide treatment.<ref>{{Cite journal \| last1 = Stupp \| first1 = R. \| last2 = Hegi \| first2 = ME. \| last3 = Mason \| first3 = WP. \| last4 = van den Bent \| first4 = MJ. \| last5 = Taphoorn \| first5 = MJ. \| last6 = Janzer \| first6 = RC. \| last7 = Ludwin \| first7 = SK. \| last8 = Allgeier \| first8 = A. \| last9 = Fisher \| first9 = B. \| title = Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. \| journal = Lancet Oncol \| volume = 10 \| issue = 5 \| pages = 459-66 \| month = May \| year = 2009 \| doi = 10.1016/S1470-2045(09)70025-7 \| PMID = 19269895 }}</ref>
	\|}		\|-
			\| BRAF-Fusion
			\| RT-PCR, RNAseq + Defuse-Analysis<ref>{{Cite journal \| last1 = McPherson \| first1 = A. \| last2 = Hormozdiari \| first2 = F. \| last3 = Zayed \| first3 = A. \| last4 = Giuliany \| first4 = R. \| last5 = Ha \| first5 = G. \| last6 = Sun \| first6 = MG. \| last7 = Griffith \| first7 = M. \| last8 = Heravi Moussavi \| first8 = A. \| last9 = Senz \| first9 = J. \| title = deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. \| journal = PLoS Comput Biol \| volume = 7 \| issue = 5 \| pages = e1001138 \| month = May \| year = 2011 \| doi = 10.1371/journal.pcbi.1001138 \| PMID = 21625565 }}</ref>
			\| [[pilocytic astrocytoma]]
			\| Diagnostic.<ref>{{Cite journal \| last1 = Hasselblatt \| first1 = M. \| last2 = Riesmeier \| first2 = B. \| last3 = Lechtape \| first3 = B. \| last4 = Brentrup \| first4 = A. \| last5 = Stummer \| first5 = W. \| last6 = Albert \| first6 = FK. \| last7 = Sepehrnia \| first7 = A. \| last8 = Ebel \| first8 = H. \| last9 = Gerss \| first9 = J. \| title = BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults. \| journal = Neuropathol Appl Neurobiol \| volume = 37 \| issue = 7 \| pages = 803-6 \| month = Dec \| year = 2011 \| doi = 10.1111/j.1365-2990.2011.01193.x \| PMID = 21696415 }}</ref>
			\|-
			\| Rela-Fusion
			\| RT-PCR, RNAseq + Defuse-Analysis
			\| supratentorial [[ependymoma]]
			\| Diagnostic and prognostic (unfavourable, when present).<ref>{{Cite journal \| last1 = Parker \| first1 = M. \| last2 = Mohankumar \| first2 = KM. \| last3 = Punchihewa \| first3 = C. \| last4 = Weinlich \| first4 = R. \| last5 = Dalton \| first5 = JD. \| last6 = Li \| first6 = Y. \| last7 = Lee \| first7 = R. \| last8 = Tatevossian \| first8 = RG. \| last9 = Phoenix \| first9 = TN. \| title = C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. \| journal = Nature \| volume = 506 \| issue = 7489 \| pages = 451-5 \| month = Feb \| year = 2014 \| doi = 10.1038/nature13109 \| PMID = 24553141 }}</ref>
			\|}

	===Other===		===Other===

Jensflorian: split out neuropathology

2016-05-13T06:08:26Z

split out neuropathology

← Older revision		Revision as of 06:08, 13 May 2016
Line 157:		Line 157:
	\|}		\|}

	===~~Other~~===		===[[Neuropathology]]===
	~~Tests for miscellaneous things~~:~~<ref name=uhn_molecular_tests>University Health Network. Molecular diagnostics - current testing. Document number: PMD10002. Version 2.0. March 30, 2011.</ref>~~		Common tests in neurooncology practice:
	{\| class="wikitable sortable" style="margin-left:auto;margin-right:auto"		{\| class="wikitable sortable" style="margin-left:auto;margin-right:auto"
	! Target		! Target
Line 168:		Line 168:
	\| PCR		\| PCR
	\| [[oligodendroglioma]]		\| [[oligodendroglioma]]
	\|		\| Prognostic and predicts response to PCV treatment.<ref>{{Cite journal \| last1 = Cairncross \| first1 = G. \| last2 = Wang \| first2 = M. \| last3 = Shaw \| first3 = E. \| last4 = Jenkins \| first4 = R. \| last5 = Brachman \| first5 = D. \| last6 = Buckner \| first6 = J. \| last7 = Fink \| first7 = K. \| last8 = Souhami \| first8 = L. \| last9 = Laperriere \| first9 = N. \| title = Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. \| journal = J Clin Oncol \| volume = 31 \| issue = 3 \| pages = 337-43 \| month = Jan \| year = 2013 \| doi = 10.1200/JCO.2012.43.2674 \| PMID = 23071247 }}</ref>
	\|-		\|-
	\| IDH1/2		\| IDH1/2
	\| PCR		\| PCR + [[IDH-1\|IDH1 R132H antibody]].
	\| [[oligodendroglioma]] [[astrocytoma]]		\| [[oligodendroglioma]] & [[astrocytoma]].
	\| ~~good~~ prognosis		\| Diagnostic and prognostic.<ref>{{Cite journal \| last1 = Hartmann \| first1 = C. \| last2 = Hentschel \| first2 = B. \| last3 = Wick \| first3 = W. \| last4 = Capper \| first4 = D. \| last5 = Felsberg \| first5 = J. \| last6 = Simon \| first6 = M. \| last7 = Westphal \| first7 = M. \| last8 = Schackert \| first8 = G. \| last9 = Meyermann \| first9 = R. \| title = Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. \| journal = Acta Neuropathol \| volume = 120 \| issue = 6 \| pages = 707-18 \| month = Dec \| year = 2010 \| doi = 10.1007/s00401-010-0781-z \| PMID = 21088844 }}</ref>
			\|-
			\| H3F3A
			\| PCR + [[H3F3A\|H3.3 K27M antibody]].
			\| [[glioblastoma]] & [[astrocytoma]].
			\| Diagnostic (K27M-mutant glioma of the midline / pediatric glioblastoma). <ref>{{Cite journal \| last1 = Sturm \| first1 = D. \| last2 = Witt \| first2 = H. \| last3 = Hovestadt \| first3 = V. \| last4 = Khuong-Quang \| first4 = DA. \| last5 = Jones \| first5 = DT. \| last6 = Konermann \| first6 = C. \| last7 = Pfaff \| first7 = E. \| last8 = Tönjes \| first8 = M. \| last9 = Sill \| first9 = M. \| title = Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. \| journal = Cancer Cell \| volume = 22 \| issue = 4 \| pages = 425-37 \| month = Oct \| year = 2012 \| doi = 10.1016/j.ccr.2012.08.024 \| PMID = 23079654 }}</ref>
			\|-
			\| MGMT
			\| Methylation-specific.
			\| [[glioblastoma]], [[astrocytoma]] & [[oligodendroglioma]].
			\| Prognostic & predicts treatment to Temozolomide treatment.<ref>{{Cite journal \| last1 = Stupp \| first1 = R. \| last2 = Hegi \| first2 = ME. \| last3 = Mason \| first3 = WP. \| last4 = van den Bent \| first4 = MJ. \| last5 = Taphoorn \| first5 = MJ. \| last6 = Janzer \| first6 = RC. \| last7 = Ludwin \| first7 = SK. \| last8 = Allgeier \| first8 = A. \| last9 = Fisher \| first9 = B. \| title = Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. \| journal = Lancet Oncol \| volume = 10 \| issue = 5 \| pages = 459-66 \| month = May \| year = 2009 \| doi = 10.1016/S1470-2045(09)70025-7 \| PMID = 19269895 }}</ref>
			\|}

			===Other===
			Tests for miscellaneous things:<ref name=uhn_molecular_tests>University Health Network. Molecular diagnostics - current testing. Document number: PMD10002. Version 2.0. March 30, 2011.</ref>
			{\| class="wikitable sortable" style="margin-left:auto;margin-right:auto"
			! Target
			! Technique
			! Disease
			! Notes
	\|-		\|-
	\| 15 STRs and amelogenin (XY) loci		\| 15 STRs and amelogenin (XY) loci

Michael: /* Other */ wikify

2015-07-31T20:47:04Z

Other: wikify

← Older revision		Revision as of 20:47, 31 July 2015
Line 178:		Line 178:
	\| PCR<ref>{{Cite journal \| last1 = Romsos \| first1 = EL. \| last2 = Vallone \| first2 = PM. \| title = Rapid PCR of STR markers: Applications to human identification. \| journal = Forensic Sci Int Genet \| volume = \| issue = \| pages = \| month = Apr \| year = 2015 \| doi = 10.1016/j.fsigen.2015.04.008 \| PMID = 25937291 }}</ref>		\| PCR<ref>{{Cite journal \| last1 = Romsos \| first1 = EL. \| last2 = Vallone \| first2 = PM. \| title = Rapid PCR of STR markers: Applications to human identification. \| journal = Forensic Sci Int Genet \| volume = \| issue = \| pages = \| month = Apr \| year = 2015 \| doi = 10.1016/j.fsigen.2015.04.008 \| PMID = 25937291 }}</ref>
	\|		\|
	\| identity testing - chimerism analysis (post-[[BMT]]),<ref>{{Cite journal \| last1 = Borrill \| first1 = V. \| last2 = Schlaphoff \| first2 = T. \| last3 = du Toit \| first3 = E. \| last4 = Marx \| first4 = M. \| last5 = Wood \| first5 = L. \| last6 = Jacobs \| first6 = P. \| title = The use of short tandem repeat polymorphisms for monitoring chimerism following bone marrow transplantation: a short report. \| journal = Hematology \| volume = 13 \| issue = 4 \| pages = 210-4 \| month = Aug \| year = 2008 \| doi = 10.1179/102453308X316059 \| PMID = 18796246 }}</ref> specimen mix-ups, [[decendent identification]]/evidence ([[forensic pathology]])		\| [[identity testing]] - chimerism analysis (post-[[BMT]]),<ref>{{Cite journal \| last1 = Borrill \| first1 = V. \| last2 = Schlaphoff \| first2 = T. \| last3 = du Toit \| first3 = E. \| last4 = Marx \| first4 = M. \| last5 = Wood \| first5 = L. \| last6 = Jacobs \| first6 = P. \| title = The use of short tandem repeat polymorphisms for monitoring chimerism following bone marrow transplantation: a short report. \| journal = Hematology \| volume = 13 \| issue = 4 \| pages = 210-4 \| month = Aug \| year = 2008 \| doi = 10.1179/102453308X316059 \| PMID = 18796246 }}</ref> specimen mix-ups, [[decendent identification]]/evidence ([[forensic pathology]])
	\|-		\|-
	\| KIT, BRAF		\| KIT, BRAF

Michael: /* Other */ tweak

2015-07-31T20:34:51Z

Other: tweak

← Older revision		Revision as of 20:34, 31 July 2015
Line 175:		Line 175:
	\| good prognosis		\| good prognosis
	\|-		\|-
			\| 15 STRs and amelogenin (XY) loci
			\| PCR<ref>{{Cite journal \| last1 = Romsos \| first1 = EL. \| last2 = Vallone \| first2 = PM. \| title = Rapid PCR of STR markers: Applications to human identification. \| journal = Forensic Sci Int Genet \| volume = \| issue = \| pages = \| month = Apr \| year = 2015 \| doi = 10.1016/j.fsigen.2015.04.008 \| PMID = 25937291 }}</ref>
	\|		\|
	\| ~~15 STRs and amelogenin~~ (XY) ~~loci~~		\| identity testing - chimerism analysis (post-[[BMT]]),<ref>{{Cite journal \| last1 = Borrill \| first1 = V. \| last2 = Schlaphoff \| first2 = T. \| last3 = du Toit \| first3 = E. \| last4 = Marx \| first4 = M. \| last5 = Wood \| first5 = L. \| last6 = Jacobs \| first6 = P. \| title = The use of short tandem repeat polymorphisms for monitoring chimerism following bone marrow transplantation: a short report. \| journal = Hematology \| volume = 13 \| issue = 4 \| pages = 210-4 \| month = Aug \| year = 2008 \| doi = 10.1179/102453308X316059 \| PMID = 18796246 }}</ref> specimen mix-ups, [[decendent identification]]/evidence ([[forensic pathology]])
	\| ~~identity testing~~
	\|
	\|-		\|-
	\| KIT, BRAF		\| KIT, BRAF

Jensflorian: /* Other */

2015-07-31T14:58:14Z

Other

← Older revision		Revision as of 14:58, 31 July 2015
Line 165:		Line 165:
	! Notes		! Notes
	\|-		\|-
	\| LOH 1p, 19q		\| LOH 1p/19q
	\| PCR		\| PCR
	\| [[oligodendroglioma]]		\| [[oligodendroglioma]]
	\|		\|
			\|-
			\| IDH1/2
			\| PCR
			\| [[oligodendroglioma]] [[astrocytoma]]
			\| good prognosis
	\|-		\|-
	\|		\|

Michael: /* Carcinoma */

2015-07-24T12:52:46Z

Carcinoma

← Older revision		Revision as of 12:52, 24 July 2015
Line 141:		Line 141:
	\|		\|
	\|-		\|-
	\| KRAS, BRAF		\| [[KRAS mutation\|KRAS]], BRAF
	\| fluorescent RFLP, real time PCR, sequencing		\| fluorescent RFLP, real time PCR, sequencing
	\| metastatic [[colorectal carcinoma]]		\| metastatic [[colorectal carcinoma]]

Michael: /* Carcinoma */ wikify

2015-07-24T12:31:07Z

Carcinoma: wikify

← Older revision		Revision as of 12:31, 24 July 2015
Line 151:		Line 151:
	\|		\|
	\|-		\|-
	\| BRAF V600E		\| [[BRAF V600E]]
	\| ARMS		\| ARMS
	\| [[papillary thyroid carcinoma]]		\| [[papillary thyroid carcinoma]]

Michael: /* Leukemia */

2014-05-09T12:50:45Z

Leukemia

← Older revision		Revision as of 12:50, 9 May 2014
Line 84:		Line 84:
	\| BCR-ABL1 t(9;22)		\| BCR-ABL1 t(9;22)
	\| RQ-PCR		\| RQ-PCR
	\| [[CML]], ALL		\| [[CML]], [[ALL]]
	\| used to detect residual disease<ref>{{Ref PCPBoD8\|175}}</ref>		\| used to detect residual disease<ref>{{Ref PCPBoD8\|175}}</ref>
	\|-		\|-
Line 119:		Line 119:
	\| 15 STR loci, amelogenin		\| 15 STR loci, amelogenin
	\| PCR		\| PCR
	\| chimerism (post BMT), identity testing		\| chimerism (post-[[BMT]]), [[identity testing]]
	\| monitor transplants, sort-out mixed-up specimens		\| monitor transplants, sort-out mixed-up specimens
	\|}		\|}